Reason for the notification
|
|
Initial notification /Amendment
|
Initial notification
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
Name
|
Smith & Nephew plc
|
LEI
|
213800ZTMDN8S67S1H61
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
|
Description
of the financial instrument, type of instrument
|
Smith
& Nephew plc ordinary shares of USD 0.20 each
|
Identification code
|
ISIN: GB0009223206
|
Nature of the transaction
|
Vesting of Smith & Nephew Global Share Plan 2020: Performance
Share Programme awards granted on 20 May 2022, and subsequent sale
of shares to cover tax liability
|
Date of Transaction
|
9 March 2025 (vesting) and 10 March 2025 (market sale)
|
Place of Transaction
|
London Stock Exchange (XLON)
|
Name
(Position)
|
Status
|
Price (£)
|
Volume
|
Aggregated information
|
Helen Barraclough
(Group General Counsel and Company Secretary)
|
PDMR
|
11.441599
|
18,951 (of which 8,939 were sold and 10,012 retained)
|
N/A Single Transaction
|
Paul Connolly
(President Global Operations)
|
PDMR
|
11.441599
|
23,831 (of which 8,143 were sold and 15,688 retained)
|
N/A Single Transaction
|
Phil Cowdy
(Chief Corporate Development and Corporate Affairs
Officer)
|
PDMR
|
11.441599
|
20,420 (of which 9,632 were sold and 10,788 retained)
|
N/A Single Transaction
|
Craig Gaffin
(President, Global Orthopaedics)
|
PDMR
|
11.441599
|
10,859 (of which 3,232 were sold and 7,627 retained)
|
N/A Single Transaction
|
Mizanu Kebede
(Chief Quality & Regulatory Affairs Officer)
|
PDMR
|
11.441599
|
24,368 (of which 9,009 were sold and 15,359 retained)
|
N/A Single Transaction
|
Elga Lohler
(Chief HR Officer)
|
PDMR
|
11.441599
|
29,821 (of which 11,866 were sold and 17,955 retained)
|
N/A Single Transaction
|
Vasant Padmanabhan
(President Research & Development ENT)
|
PDMR
|
11.441599
|
29,009 (of which 10,772 were sold and 18,237 retained)
|
N/A Single Transaction
|
Alison Parkes
(Chief Compliance Officer)
|
PDMR
|
11.441599
|
7,010 (of which 2,854 were sold and 4,156 retained)
|
N/A Single Transaction
|
Scott Schaffner
(President Sports Medicine)
|
PDMR
|
11.441599
|
12,909 (of which 4,794 were sold and 8,115 retained)
|
N/A Single Transaction
|
Reason for the notification
|
|
Initial notification /Amendment
|
Initial notification
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
Name
|
Smith & Nephew plc
|
LEI
|
213800ZTMDN8S67S1H61
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
|
Description
of the financial instrument, type of instrument
|
Smith
& Nephew plc ordinary shares of USD 0.20 each
|
Identification code
|
ISIN: GB0009223206
|
Nature of the transaction
|
Final vesting on 9 March 2025 of Deferred Bonus Share awards,
granted on 9 March 2022 under the Smith & Nephew Global Share
Plan 2020, and subsequent sale of shares to cover tax
liability
|
Date of Transaction
|
9 March 2025 (vesting) and 10 March 2025 (market sale)
|
Place of Transaction
|
London Stock Exchange (XLON)
|
Name
(Position)
|
Status
|
Price (£)
|
Volume
|
Aggregated information
|
Helen Barraclough
(Group General Counsel and Company Secretary)
|
PDMR
|
11.441599
|
1,815 (of which 857 were sold and 958 retained)
|
N/A Single Transaction
|
Phil Cowdy
(Chief Corporate Development and Corporate Affairs
Officer)
|
PDMR
|
11.441599
|
2,976 (of which 1,404 were sold and 1,572 retained)
|
N/A Single Transaction
|
Craig Gaffin
(President, Global Orthopaedics)
|
PDMR
|
11.441599
|
896 (of which 267 were sold and 629 retained)
|
N/A Single Transaction
|
Mizanu Kebede
(Chief Quality & Regulatory Affairs Officer)
|
PDMR
|
11.441599
|
752 (of which 278 were sold and 474 retained)
|
N/A Single Transaction
|
Elga Lohler
(Chief HR Officer)
|
PDMR
|
11.441599
|
4,247 (of which 1,690 were sold and 2,557 retained)
|
N/A Single Transaction
|
Vasant Padmanabhan
(President Research & Development ENT)
|
PDMR
|
11.441599
|
3,436 (of which 1,276 were sold and 2,160 retained)
|
N/A Single Transaction
|
Scott Schaffner
(President Sports Medicine)
|
PDMR
|
11.441599
|
2,496 (of which 927 were sold and 1,569 retained)
|
N/A Single Transaction
|
Reason for the notification
|
|
Initial notification /Amendment
|
Initial notification
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
Name
|
Smith & Nephew plc
|
LEI
|
213800ZTMDN8S67S1H61
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
|
Description
of the financial instrument, type of instrument
|
Smith
& Nephew plc ordinary shares of USD 0.20 each
|
Identification code
|
ISIN: GB0009223206
|
Nature of the transaction
|
Partial vesting on 9 March 2025 of Deferred Bonus Share awards,
granted on 9 March 2023 under the Smith & Nephew Global Share
Plan 2020, and subsequent sale of shares to cover tax
liability
|
Date of Transaction
|
9 March 2025 (vesting) and 10 March 2025 (market sale)
|
Place of Transaction
|
London Stock Exchange (XLON)
|
Name
(Position)
|
Status
|
Price (£)
|
Volume
|
Aggregated information
|
Helen Barraclough
(Group General Counsel and Company Secretary)
|
PDMR
|
11.441599
|
1,761 (of which 830 were sold and 931 retained)
|
N/A Single Transaction
|
Paul Connolly
(President, Global Operations)
|
PDMR
|
11.441599
|
1,995 (of which 682 were sold and 1,313 retained)
|
N/A Single Transaction
|
Phil Cowdy
(Chief Corporate Development and Corporate Affairs
Officer)
|
PDMR
|
11.441599
|
1,897 (of which 895 were sold and 1,002 retained)
|
N/A Single Transaction
|
Craig Gaffin
(President, Global Orthopaedics)
|
PDMR
|
11.441599
|
590 (of which 176 were sold and 414 retained)
|
N/A Single Transaction
|
Mizanu Kebede
(Chief Quality & Regulatory Affairs Officer)
|
PDMR
|
11.441599
|
2,040 (of which 755 were sold and 1,285 retained)
|
N/A Single Transaction
|
Elga Lohler
(Chief HR Officer)
|
PDMR
|
11.441599
|
2,985 (of which 1,187 were sold and 1,798 retained)
|
N/A Single Transaction
|
Vasant Padmanabhan
(President Research & Development ENT)
|
PDMR
|
11.441599
|
2,429 (of which 902 were sold and 1,527 retained)
|
N/A Single Transaction
|
Alison Parkes
(Chief Compliance Officer)
|
PDMR
|
11.441599
|
1,055 (of which 476 were sold and 579 retained)
|
N/A Single Transaction
|
Scott Schaffner
(President Sports Medicine)
|
PDMR
|
11.441599
|
975 (of which 362 were sold and 613 retained)
|
N/A Single Transaction
|
Reason for the notification
|
|
Initial notification /Amendment
|
Initial notification
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
Name
|
Smith & Nephew plc
|
LEI
|
213800ZTMDN8S67S1H61
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
|
Description
of the financial instrument, type of instrument
|
Smith
& Nephew plc ordinary shares of USD 0.20 each
|
Identification code
|
ISIN: GB0009223206
|
Nature of the transaction
|
Partial vesting on 8 March 2025 of Deferred Bonus Share awards,
granted on 8 March 2024 under the Smith & Nephew Global Share
Plan 2020, and subsequent sale of shares to cover tax
liability
|
Date of Transaction
|
8 March 2025 (vesting) and 10 March 2025 (market sale)
|
Place of Transaction
|
London Stock Exchange (XLON)
|
Name
(Position)
|
Status
|
Price (£)
|
Volume
|
Aggregated information
|
Helen Barraclough
(Group General Counsel and Company Secretary)
|
PDMR
|
11.441599
|
3,208 (of which 1,513 were sold and 1,695 retained.)
|
N/A Single Transaction
|
Paul Connolly
(President, Global Operations)
|
PDMR
|
11.441599
|
3,373 (of which 1,153 were sold and 2,220 retained.)
|
N/A Single Transaction
|
Phil Cowdy
(Chief Corporate Development and Corporate Affairs
Officer)
|
PDMR
|
11.441599
|
3,456 (of which 1,630 were sold and 1,826 retained.)
|
N/A Single Transaction
|
Craig Gaffin
(President, Global Orthopaedics)
|
PDMR
|
11.441599
|
1,908 (of which 567 were sold and 1,341 retained.)
|
N/A Single Transaction
|
Rohit Kashyap (President, Advanced Wound Management and Global
Commercial Operations)
|
PDMR
|
11.441599
|
3,778 (of which 1,125 were sold and 2,653 retained)
|
N/A Single Transaction
|
Mizanu Kebede
(Chief Quality & Regulatory Affairs Officer)
|
PDMR
|
11.441599
|
3,880 (of which 1,434 were sold and 2,446 retained.)
|
N/A Single Transaction
|
Elga Lohler
(Chief HR Officer)
|
PDMR
|
11.441599
|
4,839 (of which 1,927 were sold and 2,912 retained.)
|
N/A Single Transaction
|
Vasant Padmanabhan
(President Research & Development ENT)
|
PDMR
|
11.441599
|
4,868 (of which 1,808 were sold and 3,060 retained.)
|
N/A Single Transaction
|
Alison Parkes
(Chief Compliance Officer)
|
PDMR
|
11.441599
|
1,875 (of which 885 were sold and 990 retained.)
|
N/A Single Transaction
|
Scott Schaffner
(President Sports Medicine)
|
PDMR
|
11.441599
|
6,046 (of which 2,245 were sold and 3,801 retained.)
|
N/A Single Transaction
|
|
|
|
|
|
Smith & Nephew plc
|
|
|
(Registrant)
|
|
|
|
|
|
|
Date:
March 11, 2025
|
By:
|
/s/
Helen Barraclough
|
|
|
Helen
Barraclough
|
|
|
Company
Secretary
|